Articles tagged with Chlamydia
The NIH has awarded four Cooperative Research Centers to develop vaccines against syphilis, gonorrhea, and chlamydia. The centers will focus on identifying vaccine candidates that could lead to safe and effective treatments for these diseases.
Professor Thomas Rudel received a €2.5 million ERC Advanced Grant to study how Chlamydia evades the human immune system and cause chronic diseases like cervical cancer. The grant aims to develop new therapies to overcome this 'blindness' and improve treatment outcomes for Chlamydia infections.
A mathematical model estimates chlamydia's R0 value, indicating the disease's potential spread. The multi-group SIR model with age structure yields an R0 estimate between 1.0148 and 1.0535 for Japan's outbreak.
Researchers have developed a new gene therapy treatment for Chlamydia using nanotechnology, achieving a 65% success rate in preventing infection on a single dose. The treatment targets the PDGFR-beta gene to prevent Chlamydia bacteria from entering cells.
A study published in Sexually Transmitted Diseases outlines a correlation between America's eviction crisis and the high rate of sexually transmitted infections. Counties with high eviction rates have higher rates of chlamydia and gonorrhea, even after controlling for factors like poverty.
A pay-it-forward model increased gonorrhea and chlamydia testing among Chinese gay men, with 54% opting in compared to 6%. The program identified previously untested individuals and may be a promising strategy for integrated HIV/STD testing.
Researchers have discovered a Chlamydia protein that manipulates human cells by removing ubiquitin and acetylation, essential for the bacterium's survival. This finding could pave the way for treating Chlamydia with fewer antibiotics.
A 7-year trial found that continued mass azithromycin distribution prevented recurrence of trachoma but did not eliminate the infection entirely. Ocular chlamydia prevalence was significantly lower in communities with ongoing treatment compared to those discontinuing treatment.
Researchers found that Chlamydia trachomatis deactivates immune cells by activating a protein that cleaves key receptors, allowing the bacterium to evade detection. This discovery holds promise for developing targeted therapies against Chlamydia infections.
In Tanzania, trichiasis surgery patients often refuse treatment because they believe the recovery period is long. However, studies show that the recovery time is actually short, typically a few days. A new study found that educating community health workers about the procedure reduced refusals and increased knowledge about the surgery.
Researchers discovered that Chlamydia trachomatis proteins interact with host cell proteins to regulate the bacterium's exit from infected cells via lysis or membrane-bound package. Calcium ion signaling plays a crucial role in this process, and disruptions to this pathway significantly inhibit extrusion.
Researchers at Harvard Medical School have unraveled the immune cascade driving complications and tissue damage in chlamydia infections. The study reveals two distinct immune pathways: one clearing bacteria and another fueling inflammation, offering a roadmap for vaccine development and precision-targeted treatments.
Exposing the gut to chlamydia provides robust protection against subsequent genital tract and other tissue infections, according to a study published in Infection and Immunity. The discovery has significant vaccine implications for preventing genital chlamydia, particularly among young people.
A randomized controlled trial found nearly doubling of STI testing in a group using internet-accessed testing compared to face-to-face appointments. E-STI testing should be considered as a complement to existing services, increasing uptake and treatment rates.
Researchers trained staff in Tanzania to assess facial cleanliness and found reliable measures of clean faces. These findings suggest adding facial cleanliness assessments to trachoma surveys in developing countries where the infection is a public health problem.
A study found that women with a specific strain of Lactobacillus iners had an increased risk of chlamydia infection. The researchers suggest that specific signatures of vaginal microbiota may indicate increased susceptibility to acquiring STIs.
A study published in The Lancet found that exposure to the meningococcal group B vaccine reduced the likelihood of contracting gonorrhoea by approximately 31%. This is the first time a vaccine has shown any protection against gonorrhoea, offering a new avenue for vaccine development.
A change in cervical cancer screening guidelines led to a decrease in Pap testing and chlamydia testing among young women. Chlamydia testing declined by 26% in females aged 15-19, resulting in lower reported incidence rates for this age group.
US medical expenditures increased by 47% between 1996-1997 and 2011-2012, driven largely by prescription drug use. Expenditures rose in most categories except primary care physicians and home health care, with the largest increases seen in specialty physicians, emergency department visits, and prescribed medications.
Researchers found that disease incidence in states with prohibitive EPT legislation grew significantly faster than in states where EPT was allowed. States with EPT laws may see reduced rates of chlamydia infections, with an average increase of 14.1 cases per 100,000 people.
Researchers created a new model to study how chlamydia interacts with the human immune system, identifying key players IRF5 and IL-10RA. The results suggest these genes could be drug targets for new treatments.
Researchers from the University of Würzburg discovered that Chlamydia trachomatis influences mitochondria to prevent programmed cell death, allowing the bacteria to replicate. The study found that miR-30c-5p microRNA is increased in infected cells, downregulating tumor suppressor protein p53 and promoting mitochondrial division
Researchers found that PGLYRPs can inhibit chlamydia infections by targeting the bacteria's stress response system. The study confirmed that PGLYRP solutions reduced the number of chlamydial inclusions by 10 times, and improved understanding of potential antichlamydial drug targets.
Researchers at McMaster University have developed a novel vaccine candidate, BD584, which shows promise in reducing chlamydial shedding and hydrosalpinx by 95% and 87.5%, respectively. The vaccine has the potential to be widely protective against all Chlamydia trachomatis strains, including those causing trachoma.
A study presented at the APIC Annual Conference found that three-quarters of ED patients treated with antibiotics tested negative for gonorrhea or chlamydia. The research highlights the need to find a balance between treating patients and preventing unnecessary antibiotic use, which contributes to antibiotic resistance.
A study of over 1,100 patients with symptoms of gonorrhea or chlamydia found that 76.6% who received antibiotics tested negative for the STDs. The study suggests focusing on clinical predictors may improve unnecessary antibiotic prescribing in patients without true disease.
A study published in PLOS Neglected Tropical Diseases found that corrective eyelid surgery substantially increases the quality of life (QoL) for people with trachomatous trichiasis, even when vision is not improved. The surgery improves symptoms such as pain and irritation, and enables patients to work and earn an income.
Chlamydia infection rates have increased across Europe, with young people particularly affected. The European Centre for Disease Prevention and Control recommends developing national strategies for prevention and effective treatment of those infected and their partners to control the disease.
A study published in Nature Communications has discovered that genes can move from chlamydia strains in the eye to sexually transmitted strains, allowing them to infect the eye and cause Trachoma. This revelation challenges previous beliefs about Chlamydia evolution and highlights the potential for new variant Trachoma strains to emerge.
The Atlas io system uses DNA probes with bespoke electrochemical tags to detect infectious diseases in less than 30 minutes. This technology has significant benefits over existing diagnostic tests, allowing for faster results and potentially reducing the spread of sexually transmitted infections.
A University of Florida Health study found that increasing alcohol taxes can decrease gonorrhea rates by 24 percent. The tax increase resulted in 2,400 fewer statewide cases of gonorrhea in Maryland during the 18 months after it went into effect.
A new study suggests that a change in the recommended Pap smear schedule for young women under 25 may have dramatically lowered the chances of getting tested for chlamydia. With the addition of a reminder system, clinic visits led to increased chlamydia screenings among this age group.
A new vaccine has been developed that generates double protection against chlamydia by teaching the immune system to recognize and remember the bacteria as a threat. The vaccine uses charge-switching synthetic adjuvant nanoparticles to bind to the bacteria, targeting mucosal surfaces and inducing an immune response.
Research published in BMJ Open found that many UK patients with gonorrhoea are being prescribed outdated antibiotics. The study analyzed electronic health records and found that between 2000 and 2011, nearly 17,000 people were diagnosed with gonorrhoea, accounting for 6-9% of all cases in England.
A Johns Hopkins Medicine study found that nearly 14% of chlamydia infections and over 30% of gonorrhea infections in women would be missed with standard genital-only screening. Extragenital rates were significant, particularly among younger women.
Research reveals Chlamydia trachomatis breaks down protective protein p53, allowing cells to mutate and develop into cancer. The bacterium exploits this mechanism to survive within host cells, posing a potential risk for cancer development.
Researchers have uncovered how chlamydia, a leading sexually transmitted pathogen, has evolved to evade its hosts through genomic shuffling and adaptation. The study found extensive genetic variation between chlamydia families, highlighting the importance of understanding this diversity for developing new therapeutics.
The USPSTF recommends intensive behavioral counseling to reduce risky sexual behaviors among all sexually active adolescents and adults at risk for STIs. Chlamydia and gonorrhea screening is recommended for young women under 24 and older women at increased risk, including pregnant women.
A recent review suggests that chlamydia can persist in the gut even after treatment, leading to potential reinfections. The source of these reinfections is likely the GI tract, which produces a strong immune response but cannot be cured.
A new assay uses recombinase polymerase amplification to detect Chlamydia trachomatis directly from urine samples, showing high sensitivity levels and specificity. The test has the potential to be applied in numerous point-of-care settings due to its simplicity and cost-effectiveness.
Scientists have resolved the 'chlamydial anomaly' by detecting peptidoglycan in Chlamydia trachomatis. The novel method used reveals regions where the molecule is produced, confirming its presence.
Researchers found that women infected with chlamydia or gonorrhoea before pregnancy had a heightened risk of stillbirth and premature birth. Despite controlling for other factors, the study suggests that these infections may be an important predictor of adverse obstetric outcomes.
Researchers at Max Planck Institute discover Chlamydia promotes gene mutations, impairing DNA damage response and leading to uncontrolled cell growth. The infection can cause chronic damage, increasing risk of cervical and ovarian cancer.
Researchers have identified a unique protein structure in the chlamydia bug that could lead to novel diagnostic methods and treatments. The discovery may help combat this sexually transmitted disease, which affects an estimated 2.8 million people in the US each year.
Research suggests that living in a poor neighborhood as an adolescent increases the risk of getting chlamydia in young adulthood. A study published in Journal of Urban Health found that children who grew up in disadvantaged areas had a higher risk of contracting the bacterial infection, even if they didn't experience other risk factors.
A joint project between QUT and The Australian Museum has mapped the koala genome, providing insights into their immune system. The study identified genes involved in B cell and T cell activation, suggesting that koalas have a capability to protect themselves against microbial pathogens like Chlamydia.
A Monash Institute of Medical Research team has identified a protein called Interferon epsilon (IFNe) that protects females against infections, including STIs. The discovery could lead to new therapeutic opportunities and boost protective immunity.
Researchers found a low risk of developing pelvic inflammatory disease (PID) following intrauterine device (IUD) insertion. Women who were screened for gonorrhea and chlamydia on the same day as IUD insertion had an equivalent risk of PID to those who were not screened.
A computerized system helped identify adolescents in need of Chlamydia and N. gonorrhea testing in a pediatric emergency department, nearly doubling testing rates. Patients found the electronic survey quick and easy to use, with high satisfaction rates.
A researcher at Indiana University has been awarded $2.3 million to explore chlamydia genomics and develop a potential vaccine for the bacterial infectious disease. The team plans to use genetic tools to understand how the bacteria circumvents host immune systems and targets preferred tissues.
Researchers used whole genome sequencing to reveal that Chlamydia strains can swap DNA, making it harder to detect new strains and track re-infections. This knowledge is crucial for improving Chlamydia testing and implementing health policies to combat the spread of this common STI.
Researchers at Duke University Medical Center developed a new way to identify genes of harmful microbes using chemicals and genomic sequencing. This approach can rapidly pinpoint genes responsible for specific traits in Chlamydia, a common sexually transmitted infection.
Researchers at the University of Southampton have made a significant breakthrough in understanding Chlamydia trachomatis genetics, enabling the development of new treatments and potentially a vaccine. This breakthrough could lead to improved treatment options for the disease, which is often left untreated due to its asymptomatic nature.
A live-attenuated Chlamydia bacteria-based vaccine has been shown to protect monkeys from developing severe eye disease and blinding trachoma. The vaccine demonstrated robust immune responses and prevented infection in up to 50% of vaccinated monkeys.
Researchers identified a novel mechanism where Chlamydia trachomatis tricks host cells into taking up the bacteria by coating itself with a growth factor made by the cells. This disguise creates a positive feedback loop, enabling bacterial infection and spread.
Researchers at Duke University Medical Center have developed a molecule that blocks the damaging actions of Chlamydia by disarming its self-defense mechanisms. The therapy will disarm CPAF, a central weapon of Chlamydia, allowing the body to take care of the rest and ultimately lead to the death of the infected cell and the bacteria.
Researchers found that college students were more likely to talk about sexual health issues with their partners after watching a Sex and the City episode featuring Samantha and Miranda. The study showed that viewers modeled their behavior after the TV characters, having these conversations in their own lives. Almost half of participant...
A subset of severe asthmatics harbor infectious C. pneumoniae in their lungs, resulting in antibody production and increased asthma severity. Antibiotic treatment can significantly improve symptoms and even lead to a complete abolition of asthma symptoms.
A Wayne State University School of Medicine researcher has developed a potential vaccine for Chlamydia, targeting the disease's leading causes of blindness and infertility. The technology demonstrates a successful vaccine effect in an animal model, paving the way for human trials and potentially significant public health benefits.
Scientists have successfully mutated specific genes of Chlamydia bacteria using a new approach called Targeting Induced Local Lesions in Genomes (TILLING). This breakthrough could lead to better understanding of the infections and develop new strategies to prevent and control them.